<DOC>
	<DOCNO>NCT01388959</DOCNO>
	<brief_summary>This single-arm , open-label , multi-centre study evaluate efficacy safety MabThera/Rituxan ( rituximab ) patient follicular non-Hodgkin 's lymphoma minimal residual disease autologous haematopoietic stem cell transplantation ( bone marrow peripheral blood ) . Two group patient consider treatment . Group A : Patients evaluable minimal tumor mass , Group B : Patients complete response abnormal B-cell lymphoma 2 ( bcl2 ) status . Patients receive MabThera/Rituxan 375 mg/m2 intravenously every week . The anticipated time study treatment 4 week .</brief_summary>
	<brief_title>A Study MabThera/Rituxan ( Rituximab ) Patients With Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , 1875 year age Diagnosis follicular nonHodgkin 's lymphoma ( FNHL ) Previously treat chemotherapy autologous haemotopoietic stem cell transplantation ( bone marrow peripheral blood cell ) Active viral hepatitis Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Patients willing sign inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>